Sometimes with biotech stocks, what a company considered to be good news clashes with what the market is expecting. That was true on Oct. 24 when Intellia Therapeutics (NASDAQ: NTLA) announced some ...
Investigators assessed tolerability, safety, and efficacy of low-intensity extracorporeal shock wave therapy for treating mild to moderate SUI in women.
CA inhibitors (CAIs) are used in therapy as diuretic and antiglaucoma agents but also show anti-obesity and antitumour effects. Some compounds are in clinical development for such applications ...